JP5045879B2 - A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver - Google Patents
A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver Download PDFInfo
- Publication number
- JP5045879B2 JP5045879B2 JP2006158466A JP2006158466A JP5045879B2 JP 5045879 B2 JP5045879 B2 JP 5045879B2 JP 2006158466 A JP2006158466 A JP 2006158466A JP 2006158466 A JP2006158466 A JP 2006158466A JP 5045879 B2 JP5045879 B2 JP 5045879B2
- Authority
- JP
- Japan
- Prior art keywords
- effect
- group
- improving
- insulin resistance
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010022489 Insulin Resistance Diseases 0.000 title claims description 21
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims description 20
- 239000000203 mixture Substances 0.000 title claims description 18
- 235000019786 weight gain Nutrition 0.000 title claims description 18
- 230000004584 weight gain Effects 0.000 title claims description 15
- 208000004930 Fatty Liver Diseases 0.000 title claims description 10
- 206010019708 Hepatic steatosis Diseases 0.000 title claims description 10
- 208000010706 fatty liver disease Diseases 0.000 title claims description 10
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims description 10
- 230000000694 effects Effects 0.000 title description 26
- 229940050071 chromium nicotinic acid complex Drugs 0.000 claims description 20
- 229940072113 onion extract Drugs 0.000 claims description 17
- 239000011651 chromium Substances 0.000 description 25
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 229910052804 chromium Inorganic materials 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 16
- 208000008589 Obesity Diseases 0.000 description 14
- 235000020824 obesity Nutrition 0.000 description 14
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 239000000843 powder Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 241000234282 Allium Species 0.000 description 8
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 8
- 102000016267 Leptin Human genes 0.000 description 8
- 108010092277 Leptin Proteins 0.000 description 8
- 235000021588 free fatty acids Nutrition 0.000 description 8
- 229940039781 leptin Drugs 0.000 description 8
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 235000012631 food intake Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 102100031775 Leptin receptor Human genes 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、クロムとタマネギエキスを混合したことからなる、短期間でインスリン抵抗性の改善効果、体重増加の抑制効果、及び脂肪肝の予防及び改善効果を有する混合物に関する。特にクロムが３価クロム−ニコチン酸錯体である混合物に関する。 The present invention relates to a mixture comprising a mixture of chromium and onion extract, which has an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver in a short period of time. In particular, it relates to a mixture in which chromium is a trivalent chromium-nicotinic acid complex.
従来より、糖尿病に関する研究が日本及び諸外国でなされているが、本発明者らも糖尿病に関する研究を行っており、特にインスリン抵抗性の改善について研究した。 Conventionally, research on diabetes has been conducted in Japan and other countries. The present inventors have also conducted research on diabetes, and in particular, studied improvement of insulin resistance.
インスリン抵抗性とは、血糖を下げる唯一のホルモンであるインスリンの作用が効かず、肝臓や骨格筋、脂肪細胞などでの糖の取込が抑制を受ける症状である。本来、体は血糖のコントロールとして、食事で血液中の糖濃度が上昇すると、膵臓ランゲルハンス島のβ細胞よりインスリンが分泌され、肝臓や骨格筋、脂肪細胞のインスリン受容体に結合し、糖の取込が促進される。ところが、β細胞からのインスリン分泌は充分量あっても、各器官でのインスリン受容体やその後の経路に障害があると、インスリンを感受出来ず糖の取込がなされない。つまりインスリンの感受性が低下することをインスリン抵抗性といい、インスリン抵抗性があると糖尿病や高脂血症、高血圧が生じやすく、動脈硬化が進展するものである。 Insulin resistance is a symptom in which the action of insulin, which is the only hormone that lowers blood sugar, does not work, and the uptake of sugar in the liver, skeletal muscle, fat cells, etc. is suppressed. Essentially, as the body controls blood sugar, when the sugar concentration in the blood rises in the diet, insulin is secreted from the β cells of the pancreatic islets of Langerhans and binds to insulin receptors in the liver, skeletal muscle, and adipocytes, and the sugar is taken up. Is promoted. However, even if there is a sufficient amount of insulin secretion from β cells, if there is a disorder in the insulin receptor and the subsequent pathway in each organ, insulin cannot be sensed and sugar cannot be taken up. That is, a decrease in insulin sensitivity is referred to as insulin resistance. If there is insulin resistance, diabetes, hyperlipidemia, and hypertension are likely to occur, and arteriosclerosis develops.
肥満（体重増加）は脂肪細胞の占める割合が増大することに起因するが、巨大化した脂肪細胞は、遊離脂肪酸やＴＮＦ−α，レジスチンなどのインスリン抵抗性惹起物質を分泌することが知られている。
即ち、肥満がインスリン抵抗性と関係があることが知られている。
Obesity (weight gain) is caused by an increase in the proportion of fat cells, but giant fat cells are known to secrete insulin resistance-inducing substances such as free fatty acids, TNF-α, and resistin. Yes.
That is, it is known that obesity is related to insulin resistance.
近年の飽食と機械文明、車社会の影響、遺伝的な背景により必然的な内臓脂肪の蓄積による肥満症が、生活習慣病（メタボリック症候群）の鍵となっている。肥満の度合はBMI（Body Mass Index）を用いて判定され、体重Kg／（身長m）2により算出する。日本肥満学会肥満症診断基準検討委員会(2000年)ではBMI25以上が肥満であると規定している。
平成15年厚生省が行った国民栄養調査によれば、男性の肥満者の割合は、いずれの年齢階級においても昭和58年に比べ増加していた。またBMIが25以上で、男性のウエスト周囲径85cm以上、女性のウエスト周囲径90cm以上を上半身肥満の疑いとし、調査したところ男性で24.9％、女性で13.8％であった。
このように肥満、即ち体重の増加は近年重要な問題になっている。
Obesity due to the accumulation of visceral fat due to satiety and machine civilization in recent years, the influence of the car society, and genetic background is the key to lifestyle-related diseases (metabolic syndrome). The degree of obesity is determined using BMI (Body Mass Index) and is calculated by weight Kg / (height m) 2 . The Japan Obesity Society Obesity Diagnostic Standards Review Committee (2000) stipulates that BMI25 and above are obese.
According to the National Nutrition Survey conducted by the Ministry of Health and Welfare in 2003, the proportion of male obese people increased in all age groups compared to 1983. In addition, BMI was 25 or more, male waist circumference 85cm or more, female waist circumference 90cm or more was suspected of being upper body obesity, and it was 24.9% for men and 13.8% for women.
Thus, obesity, that is, an increase in weight has become an important problem in recent years.
そこで、本発明者らは、インスリン抵抗性の改善、肥満の抑制、即ち体重増加の抑制について鋭意研究を行った。 Therefore, the present inventors conducted intensive studies on improvement of insulin resistance, suppression of obesity, that is, suppression of weight gain.
しかして、本発明者らはまずタマネギに着目した。タマネギについては種々研究がなされており、抗糖尿病効果があること（例えば、特許文献１，２参照。）、脂質低下作用があること（例えば、特許文献３参照。）等が知られている。 Therefore, the present inventors first focused on the onion. Various studies have been made on onion, and it is known that it has an anti-diabetic effect (for example, see Patent Documents 1 and 2), and has a lipid lowering action (for example, see Patent Document 3).
次にクロムがインスリンの働きを助けて正常な血糖の維持を図ることが知られており、このクロムに着目した。
3価クロムは，非経口的に多量投与すると皮膚の炎症を起こすことがあるが，経口で少量投与すれば毒性はない。6価は強い毒性を示すことが知られている。
しかし、クロムに関しては、体内に吸収されにくいという問題があったが、ザ ウイリアム セロイ グループが発明し、特許第３０１４１０９号として特許された３価クロム−ニコチン酸錯体があり、この３価クロム−ニコチン酸錯体は体内に非常に吸収されやすい、ということが分かった（例えば、非特許文献１参照。）。
Next, it was known that chromium helps insulin function to maintain normal blood sugar, and we focused on this chromium.
Trivalent chromium may cause skin irritation when administered parenterally in large doses, but is not toxic if administered in small doses orally. Hexavalent is known to show strong toxicity.
However, chromium has a problem that it is difficult to be absorbed into the body, but there is a trivalent chromium-nicotinic acid complex invented by the William Celoi Group and patented as Patent No. 3014109. It turned out that an acid complex is very easy to be absorbed in the body (for example, refer nonpatent literature 1).
しかしながら、タマネギに関し、体重増加の抑制については、いずれの文献にも示唆や実験例の記載がなされていない。また、タマネギのインスリン抵抗性の改善についても、ほぼ３ヶ月以上の長期投与により改善の可能性が示唆されるものの（例えば、特許文献３参照。）、明確な実験や証明がなされている文献がない。さらにクロムとの相乗効果に関しては、いずれの文献にも記載されていない。 However, there is no suggestion or description of experimental examples in terms of suppression of weight gain for onions. In addition, although there is a suggestion that improvement of onion insulin resistance may be improved by long-term administration of about 3 months or longer (see, for example, Patent Document 3), there are documents on which clear experiments and proofs have been made. Absent. Furthermore, no synergistic effect with chromium is described in any document.
上述のことから、本発明者らはタマネギエキスと３価クロム、特に３価クロム−ニコチン酸錯体を混合することにより、インスリン抵抗性の改善・体重増加の抑制の相乗効果が期待出来るのではないかと考えた。
そこで鋭意研究の結果、タマネギエキスと３価クロム、特に３価クロム−ニコチン酸錯体の混合物は、インスリン抵抗性の改善、体重増加の抑制に顕著な効果があることを発見した。さらに脂肪肝の予防及び改善にも顕著な効果があることをも発見した。
From the above, the present inventors cannot expect a synergistic effect of improving insulin resistance and suppressing body weight gain by mixing onion extract and trivalent chromium, particularly trivalent chromium-nicotinic acid complex. I thought.
As a result of intensive studies, it was discovered that a mixture of onion extract and trivalent chromium, particularly a trivalent chromium-nicotinic acid complex, has a remarkable effect in improving insulin resistance and suppressing weight gain. It was also discovered that there is a significant effect on the prevention and improvement of fatty liver.
そこで、本発明は、インスリン抵抗性の改善、体重増加（肥満）の抑制の効果、及び脂肪肝の予防及び改善効果を有する混合物を提供することを目的とする。 Then, an object of this invention is to provide the mixture which has an improvement effect of insulin resistance, the effect of suppression of weight gain (obesity), and the prevention and improvement effect of fatty liver.
前記目的を達成するため、本発明のインスリン抵抗性の改善効果、体重増加の抑制効果、及び脂肪肝の予防及び改善効果を有する混合物は３価クロムとタマネギエキスを混合したことからなる。 In order to achieve the above-mentioned object, the mixture having the effect of improving insulin resistance, the effect of suppressing weight gain, and the effect of preventing and improving fatty liver according to the present invention comprises a mixture of trivalent chromium and onion extract.
又、前記３価クロムが３価クロム−ニコチン酸錯体であることが好適である。 The trivalent chromium is preferably a trivalent chromium-nicotinic acid complex.
３価クロム−ニコチン酸錯体の構造式は下記の通りである。
本発明により、２週間〜４週間程度の短期間で、インスリン抵抗性の改善効果、体重増加（肥満）の抑制効果、及び脂肪肝の予防及び改善効果を有する混合物を提供することが出来る。 According to the present invention, it is possible to provide a mixture having an effect of improving insulin resistance, an effect of suppressing weight gain (obesity), and an effect of preventing and improving fatty liver in a short period of about 2 to 4 weeks.
製造例は下記の通りである。
北海道産タマネギ10kgを水洗機で２回水洗し直ちに釜に入れ100℃で加熱煮沸した。得られた煮沸済みタマネギをフェザーミルで破砕し搾汁機で搾汁し、搾汁液9.5kgを得た。遠心薄膜式減圧濃縮機を用いて、加熱温度92℃、蒸発温度42℃および圧力15mmHgで減圧濃縮を行い、濃縮エキス0.9kgを得た。減圧濃縮の際留出してくる成分を活性炭層に通して吸着させた。吸着物をエタノールで溶出させ得られた溶液からエタノールを蒸発により除去し、残存する成分1.5gを得た。これを先に得た濃縮エキスに均一に加えタマネギエキス0.9kgを得た。得られたエキスにデキストリンを加え、噴霧乾燥して粉末とした。
Production examples are as follows.
10 kg of Hokkaido onion was washed twice with a washing machine, immediately put in a kettle and boiled at 100 ° C. The obtained boiled onion was crushed with a feather mill and squeezed with a squeezer to obtain 9.5 kg of squeezed liquid. Using a centrifugal thin film vacuum concentrator, vacuum concentration was performed at a heating temperature of 92 ° C., an evaporation temperature of 42 ° C., and a pressure of 15 mmHg to obtain 0.9 kg of a concentrated extract. Components distilled out during concentration under reduced pressure were adsorbed through an activated carbon layer. Ethanol was removed by evaporation from the solution obtained by eluting the adsorbate with ethanol to obtain 1.5 g of the remaining component. This was uniformly added to the previously obtained concentrated extract to obtain 0.9 kg of onion extract. Dextrin was added to the obtained extract and spray dried to obtain a powder.
水にニコチン酸を添加し、溶解させ、次に３価の塩化クロムを添加し、撹拌する。撹拌することにより３価クロム−ニコチン酸錯体の沈殿物が得られる。この沈殿物を破砕機で微少に破砕し、乾燥させ粉末にする。 Add and dissolve nicotinic acid in water, then add trivalent chromium chloride and stir. By stirring, a precipitate of a trivalent chromium-nicotinic acid complex is obtained. This precipitate is finely crushed with a crusher and dried to a powder.
得られたタマネギの粉末及び３価クロム又は３価クロム−ニコチン酸錯体の粉末を混合機を使用し、混合し、混合物を得る。 The obtained onion powder and trivalent chromium or trivalent chromium-nicotinic acid complex powder are mixed using a mixer to obtain a mixture.
配合比率としては、タマネギエキスの粉末約99.00〜99.99重量％に対し、クロム含有率10重量%の３価クロム−ニコチン酸錯体の粉末約1.00〜0.01重量％が好適である。 The blending ratio is preferably about 1.00 to 0.01% by weight of a trivalent chromium-nicotinic acid complex powder having a chromium content of 10% by weight with respect to about 99.00 to 99.99% by weight of onion extract powder.
タマネギエキスの粉末の製造方法及び３価クロム並びに３価クロム−ニコチン酸錯体の粉末の製造方法は、従来より行われている方法であるが、これらの粉末の混合物を通常行われている方法で錠剤、カプセル等にして、健康食品として使用したり、さらに、これらの粉末の混合物を、必要に応じて製剤学的に受容可能な添加物（例えば、賦形剤、界面活性剤等）を加えることにより薬剤にすることが出来、薬剤として使用することも出来る。 The method for producing onion extract powder and the method for producing trivalent chromium and trivalent chromium-nicotinic acid complex powder are conventional methods, but a mixture of these powders is usually used. Use as tablets, capsules, etc. as health foods, and add pharmaceutically acceptable additives (eg, excipients, surfactants, etc.) to these powder mixtures as necessary. Can be used as a medicine, and can be used as a medicine.
以下実施例について記述する。 Examples will be described below.
目的
３価クロム−ニコチン酸錯体とオニオン（タマネギエキス）の肥満、インスリン抵抗性への改善効果に対する相乗効果の検討
方法
Zucker fa/faは多食であり肥満モデルとして、また高インスリン血症、インスリン抵抗性モデルとしても用いられている。そこで、本研究では糖耐性因子と考えられる３価クロム−ニコチン酸錯体とタマネギエキスの相乗効果について検討を行った。
実験動物
８週令 Zucker +/+ （非肥満モデル）
８週令 Zucker fa/fa （肥満モデル）
Objective Examination of the synergistic effect of trivalent chromium-nicotinic acid complex and onion (onion extract) on the effect of improving obesity and insulin resistance
Zucker fa / fa is a polyphasic and is used as an obesity model, and also as a model for hyperinsulinemia and insulin resistance. In this study, we investigated the synergistic effect of trivalent chromium-nicotinic acid complex, which is considered to be a glucose tolerance factor, and onion extract.
Experimental animal 8 weeks old Zucker + / + (non-obese model)
8 weeks old Zucker fa / fa (obesity model)
グループ
食餌組成
測定項目
食餌摂取量、体重増加量、肝臓重量、腎臓重量、精巣周囲脂肪重量、耐糖能試験、血糖値、血清インスリン、血清総コレステロール、血清トリグリセリド、血清遊離脂肪酸、血清レプチン
統計処理
Ｔ検定で有意差検定を行った。Ｖ群に対して両側検定p<0.05(*)、p<0.01(**)を表わす。
Measurement items Dietary intake, body weight gain, liver weight, kidney weight, testicular fat weight, glucose tolerance test, blood glucose level, serum insulin, serum total cholesterol, serum triglyceride, serum free fatty acid, serum leptin Statistical processing Significant in T test A difference test was performed. Two-sided test p <0.05 (*), p <0.01 (**) is represented for group V.
結果
体重増加、総食餌摂取量
28日間の飼育期間中に体重、食餌摂取量を測定したところ、総食餌摂取量においてCon群を除いてV、Cr、O、CrO群で差は認められなかった。しかしながら体重増加の抑制においてCrO群は、V群と比較して有意な差が認められた。それに対して、Cr群およびO群は、V群と比較して有意な差は認められなかった。
Results Weight gain, total food intake
When the body weight and food intake were measured during the 28-day breeding period, there was no difference in the total food intake between the V, Cr, O, and CrO groups except for the Con group. However, there was a significant difference between the CrO group and the V group in suppressing body weight gain. In contrast, the Cr group and the O group were not significantly different from the V group.
すなわち、体重はV群と比較してCrO群にのみ上昇抑制傾向が認められ、21日目以降有意な上昇抑制が認められた。
これにより、３価クロム−ニコチン酸錯体のみ、もしくはタマネギエキスのみには体重増加の抑制効果が認められなかったにもかかわらず、本発明の混合物には体重増加の抑制効果(肥満予防効果)があることが認められた。又、短期間で体重増加の抑制効果があることが認められた。
That is, the body weight increased only in the CrO group as compared to the V group, and a significant increase was observed after the 21st day.
As a result, although the trivalent chromium-nicotinic acid complex alone or the onion extract alone did not show an effect of suppressing weight gain, the mixture of the present invention has an effect of suppressing weight gain (anti-obesity effect). It was recognized that there was. Moreover, it was recognized that there is an effect of suppressing weight gain in a short period of time.
肝臓、腎臓、精巣周囲脂肪の重量
肝臓重量において、CrO群は、V群と比較して有意な差が認められた。それに対して、Cr群およびO群は、V群と比較して有意な差は認められなかった。Con群と比較して、fa/faの肝臓は明らかに脂肪肝であった。
これにより、３価クロム−ニコチン酸錯体のみ、もしくはタマネギエキスのみには脂肪肝予防及び改善効果が認められなかったにもかかわらず、３価クロム−ニコチン酸錯体とタマネギエキスの混合物には脂肪肝の予防・改善効果があるという顕著な効果が認められた。
Liver, kidney, and testicular fat weights In the liver weight, the CrO group was significantly different from the V group. In contrast, the Cr group and the O group were not significantly different from the V group. Compared to the Con group, the fa / fa liver was clearly fatty liver.
As a result, even when the trivalent chromium-nicotinic acid complex alone or the onion extract alone did not have the effect of preventing and improving fatty liver, the mixture of the trivalent chromium-nicotinic acid complex and the onion extract contained fatty liver. A remarkable effect was observed that there was a preventive / improving effect.
なお、前述の体重増加が抑制された原因については不明であるものの、CrO群でのみ有意に抑制が認められた(p<0.05の有意差があった)ことにより、臓器の脂肪沈着が体重に反映されている可能性も考えられる。また、腎臓および精巣周囲脂肪の重量において、Cr群、O群、CrO群は、V群と比較して有意な差は認められなかったため、作用が各臓器に特異的であることも示唆された。 Although the cause of the suppression of the above-mentioned weight gain is unknown, significant suppression was observed only in the CrO group (there was a significant difference of p <0.05). It is possible that this is reflected. In addition, there was no significant difference in the weight of kidney and peritestinal fat in the Cr, O, and CrO groups compared to the V group, suggesting that the action is specific to each organ. .
耐糖能試験
実験開始2週間目(9週令)および4週間目(11週令)の各群のラットにおいて耐糖能試験を行った。16時間絶食後、各群のラットにD-グルコース2g/体重kgを強制摂取させ、その後の血糖値を経時的に測定した。その結果、CrO群は、V群と比較してD-グルコース投与後15分に有意に上昇が抑制され、120分に有意に低下することが認められた。それに対して、Cr群およびO群は、V群と比較して有意な差は認められなかった。
Glucose tolerance test Glucose tolerance test was performed on rats in each group at 2 weeks (9 weeks old) and 4 weeks (11 weeks old). After fasting for 16 hours, rats of each group were forcibly ingested 2 g / kg body weight of D-glucose, and blood glucose levels thereafter were measured over time. As a result, in the CrO group, the increase was significantly suppressed 15 minutes after administration of D-glucose and significantly decreased at 120 minutes, compared with the V group. In contrast, the Cr group and the O group were not significantly different from the V group.
血清インスリン、血糖値
解剖時の血清インスリンおよび血糖値を測定した。その結果、血清インスリン量において、Cr群、O群、CrO群は、V群と比較して有意な差は認められなかった。血糖値において、CrO群は、V群と比較して有意な差が認められた。それに対して、Cr群およびO群は、V群と比較して有意な差は認められなかった。
Serum insulin and blood glucose level Serum insulin and blood glucose level at the time of dissection were measured. As a result, in the serum insulin amount, the Cr group, the O group, and the CrO group were not significantly different from the V group. In the blood glucose level, a significant difference was observed in the CrO group compared to the V group. In contrast, the Cr group and the O group were not significantly different from the V group.
以上によると、耐糖能試験において、飼育2週間目でV群と比較してCrO群で15分と120分に有意差がつき、4週間目には30分にCrO群で有意な上昇抑制が認められ、120分にはCrO群で非肥満の+/+ラットの血糖レベルまで減少するといいう顕著な効果を示しているにもかかわらず、血清インスリン量はCr群、O群、V群と比較して差はなかった。
これらの結果により、３価クロム−ニコチン酸錯体とタマネギエキスの併用はインスリン分泌能に影響は与えず、感受性を改善し、糖の取込みを促進したものと考えられる。
すなわち、３価クロム−ニコチン酸錯体のみ及びタマネギエキスのみにはインスリン抵抗性改善の効果が認められなかったにもかかわらず、３価クロム−ニコチン酸錯体とタマネギエキスの混合物にはインスリン抵抗性改善の効果が、２週間から４週間という短期間で顕著に認められた。
According to the above, in the glucose tolerance test, there was a significant difference in the CrO group at 15 minutes and 120 minutes compared to the V group in the second week of breeding, and a significant increase suppression in the CrO group at 30 minutes in the fourth week. Despite the remarkable effect of reducing blood glucose levels in non-obese + / + rats in the CrO group at 120 minutes, serum insulin levels in the Cr, O, and V groups There was no difference compared.
From these results, it is considered that the combined use of the trivalent chromium-nicotinic acid complex and the onion extract did not affect the insulin secretion ability, improved the sensitivity, and promoted the sugar uptake.
That is, only the trivalent chromium-nicotinic acid complex and the onion extract alone showed no improvement in insulin resistance, but the mixture of the trivalent chromium-nicotinic acid complex and the onion extract improved insulin resistance. Was noticeable in a short period of 2 to 4 weeks.
血清総コレステロール（TC）、血清トリグリセリド（TG）、血清遊離脂肪酸（FFA）、レプチン
TC、FFA、レプチンにおいて、Cr群、O群、CrO群は、V群と比較して有意な差は認められなかった。TGにおいて、CrO群は、V群と比較して有意な差が認められた。それに対して、Cr群およびO群は、V群と比較して有意な差は認められなかった。FFAにおいて、CrO群は、V群と比較して低下傾向にあったが、有意な差は認めらなかった。Zucker fa/fa はレプチン受容体変異により血清レプチン量が高値であることが知られているが、本試験ではレプチン量を変化させることはなかった。
Serum total cholesterol (TC), serum triglyceride (TG), serum free fatty acid (FFA), leptin
In TC, FFA, and leptin, the Cr group, the O group, and the CrO group were not significantly different from the V group. In TG, a significant difference was observed between the CrO group and the V group. In contrast, the Cr group and the O group were not significantly different from the V group. In FFA, the CrO group tended to be lower than the V group, but no significant difference was observed. Zucker fa / fa is known to have high serum leptin levels due to leptin receptor mutations, but it did not change leptin levels in this study.
血清TCにはfa/fa間で変化がなかったが、血清TGはV群と比較してCr、O群で低下傾向、CrO群で有意な低下が認められた。また、有意差はないもののFFAにおいてもV群よりCrO群で低下傾向を示した。インスリン作用不足は、リポ蛋白リパーゼ活性を抑制し、カイロミクロンやVLDLの異化が障害され、血液中のTGが増加し、高TG血症になる。逆にホルモン感受性リパーゼは促進されるため脂肪分解が起こり、脂肪組織で中性脂肪が分解されて、FFAとグリセロールが、血中に遊離され、高FFA血症になる。結果から３価クロム−ニコチン酸錯体とタマネギエキスの併用はインスリンの感度を高くしていることを証明していると推察される。 Serum TC did not change between fa / fa, but serum TG was decreased in Cr and O groups and significantly decreased in CrO group compared to V group. Although there was no significant difference, the FFA also showed a lower tendency in the CrO group than in the V group. Insufficiency of insulin suppresses lipoprotein lipase activity, impairs chylomicron and VLDL catabolism, increases blood TG, and leads to hyperTGemia. Conversely, hormone-sensitive lipase is promoted, causing lipolysis, and triglycerides are broken down in adipose tissue, releasing FFA and glycerol into the blood, resulting in hyper-FFA. From the results, it is presumed that the combined use of the trivalent chromium-nicotinic acid complex and the onion extract proves that the sensitivity of insulin is increased.
今回用いたZucker fa/faは摂食抑制やエネルギー消費をもたらすホルモンであるレプチンの受容体が変異しているため、レプチンの作用が働かず、多食を引き起こした。血清レプチン測定の結果は、fa/fa間で変化が認められず、また総食餌摂取量の結果から多食を食い止めることは出来なかった。 The Zucker fa / fa used in this study was mutated in the receptor for leptin, a hormone that suppresses food intake and consumes energy, so that the action of leptin did not work, resulting in multiple eating. The results of serum leptin measurement did not change between fa / fa, and it was not possible to stop eating too much from the results of total food intake.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006158466A JP5045879B2 (en) | 2006-06-07 | 2006-06-07 | A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006158466A JP5045879B2 (en) | 2006-06-07 | 2006-06-07 | A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007326800A JP2007326800A (en) | 2007-12-20 |
| JP5045879B2 true JP5045879B2 (en) | 2012-10-10 |
Family
ID=38927526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006158466A Active JP5045879B2 (en) | 2006-06-07 | 2006-06-07 | A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5045879B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201002332A (en) | 2008-07-07 | 2010-01-16 | Univ Nat Chunghsing | Composition for preventing and controlling fatty liver disease |
| US9801833B2 (en) * | 2013-07-22 | 2017-10-31 | Nestec S.A. | Compositions and methods using tiglic aldehyde |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1077232A (en) * | 1996-09-03 | 1998-03-24 | M S C:Kk | Preventive and therapeutic agent for complication by diabetic |
| US5989294A (en) * | 1998-07-29 | 1999-11-23 | Marlow; Aaron L. | Ball-and-socket joint, particularly a prosthetic hip joint |
| JP2001139478A (en) * | 1999-11-16 | 2001-05-22 | Marine Bio Kk | Extracted compound containing small amount mineral component from coral sand |
| JP3633852B2 (en) * | 2000-06-06 | 2005-03-30 | 伶輝 程 | Trivalent chromium composite, its dairy product and its production method |
| ES2223924T3 (en) * | 2000-09-21 | 2005-03-01 | Nutrition 21, Inc. | COMPOSITIONS CONTAINING CHROME FOR THE TREATMENT OF DIABETES, REDUCTION OF BODY FAT, IMPROVEMENT OF INSULIN SENSITIVITY, REDUCTION OF HYPERGLYCEMIA AND REDUCTION OF HYPERCHOLESTEREMIA. |
| JP2002332236A (en) * | 2001-05-09 | 2002-11-22 | Shinbijumu:Kk | Mineral-containing composition |
| US7119110B2 (en) * | 2001-10-05 | 2006-10-10 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome |
| JP4477806B2 (en) * | 2001-12-25 | 2010-06-09 | 有限会社エム・エス・シー | Method for producing active ingredient of onion, active ingredient of onion by the production method and health food |
| WO2003090671A2 (en) * | 2002-04-23 | 2003-11-06 | Nutrition 21, Inc. | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
| JP2004115491A (en) * | 2002-09-24 | 2004-04-15 | Ryusendo:Kk | Glycation suppressing agent for aminophospholipid |
| JP4813023B2 (en) * | 2004-03-03 | 2011-11-09 | 日本新薬株式会社 | Health foods and drugs |
| TW200605902A (en) * | 2004-08-05 | 2006-02-16 | Maxluck Biotechnology Corp | Composition for lowering blood lipid |
-
2006
- 2006-06-07 JP JP2006158466A patent/JP5045879B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007326800A (en) | 2007-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2380103C2 (en) | Agent for decreasing insulin resistance | |
| RU2379313C2 (en) | Preparation to improve condition in insulin resistance | |
| JP5045879B2 (en) | A mixture having an effect of improving insulin resistance, an effect of suppressing weight gain, and an effect of preventing and improving fatty liver | |
| RU2379037C2 (en) | Preparation to reduce insulin resistance | |
| EP1644007B1 (en) | Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes | |
| JP2003252785A (en) | Mixture of panax quinqefolium l. and method for producing the same | |
| US20080268069A1 (en) | Mixture having effect of improving insulin resistance, effect of suppressing body weight gain, and effect of preventing and improving fatty liver | |
| JP4136850B2 (en) | Cell differentiation promoter | |
| JP6306634B2 (en) | Composition for food | |
| JP2009029786A (en) | Pancreatic lipase inhibitor, its production method and therapeutic method | |
| JP2009242342A (en) | Adipose tissue inflammation suppressor, fatty acid synthesis inhibitor, and prophylactic agent for lifestyle-related diseases and functional food containing the same | |
| WO2015041235A1 (en) | Use of food material for treating lifestyle-related diseases | |
| US7846905B2 (en) | Agent for inhibiting visceral fat accumulation | |
| JP5926469B2 (en) | Muscle sugar uptake promoter, hyperglycemia improving agent, and preventive or therapeutic agent for diabetes and / or diabetic complications | |
| JP2015059088A (en) | Foods having insulin resistance improving action and insulin resistance-improving agents | |
| Rabeh et al. | Effect of Grilled Meat Supplemented with Cinnamon, Green Coffee and Cardamom on Body Weight of Obese Rats. | |
| JP2021109858A (en) | Agent for preventing or improving metabolic syndrome | |
| Lee et al. | Effects of functional extracts made from fermented plants on serum glucose and lipids level in streptozotocin-induced diabetic rats | |
| 김희준 | The effects of chitosan oligosaccharide supplementation on glucose control in subjects with pre-diabetes | |
| WO2005115425A1 (en) | Composition comprising fermented tea extract as the main component and having effect of incrasing adiponectin | |
| KR20170013558A (en) | Non-Alcoholic Steatohepatitis Preventive Health Food and Manufacturing Method Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120313 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120410 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120626 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120703 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150727 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5045879 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |